Investor Toolbox
Listen to Call
Recording not yet available.
Read Transcript
Transcript not yet available.
View Infographic
Infographic not yet available.
ABBV Coverage
Event
AbbVie (ABBV) AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
Apr 28, 2026
Event
AbbVie (ABBV) RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitor
Apr 28, 2026
News
AbbVie’s Q1 2026 Preview: Can Skyrizi and Rinvoq Sustain a $7B Quarterly Immunology Run Rate?
Apr 27, 2026
Event
AbbVie (ABBV) AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn’s Disease
Apr 27, 2026
Transcript
AbbVie (ABBV) Q4 2025 Earnings Call Transcript
Apr 23, 2026
News
S&P 500 Gains as Risk-On Rotation Sends Energy Up 1.84%, Utilities Down 1.68%
Feb 19, 2026
Transcript
AbbVie (ABBV) Q2 2025 Earnings Call Transcript
Jan 22, 2026
Transcript
AbbVie (ABBV) Q3 2025 Earnings Call Transcript
Jan 22, 2026